Switching From Gilenya to Lemtrada May Not Be Optimal Choice, Study Says
Previous treatment with oral Gilenya (fingolimod)Â is associated with a suboptimal response to Lemtrada (alemtuzumab) and an increased risk of secondary autoimmune disorders in multiple sclerosis (MS) patients, a study reports. However, Lemtrada showed an efficacy in patients switching from various other disease…